The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Site Search
Showing 31 - 40 of 307 results
News
|
May 17, 2017
|
3 min read
I've lived my whole life like it has an early expiration date. Recently, a drug was FDA-approved that could change that. I'm grateful, but I'm also scared…
Amy Braid
|
5 min read
Bill Would Remove Financial Penalties for Participating in Research Studies
Press Release
|
Sept. 16, 2009
|
4 min read
Press Release
|
March 19, 2011
|
3 min read
Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease
Press Release
|
June 22, 2011
|
2 min read
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Press Release
|
Jan. 31, 2012
|
5 min read
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
Press Release
|
April 25, 2012
|
3 min read
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
Press Release
|
May 10, 2012
|
5 min read
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
Press Release
|
June 24, 2014
|
5 min read
Press Release
|
Jan. 30, 2015
|
1 min read